Liposomal formulation of new arsenic schiff base complex as drug delivery agent in the treatment of acute promyelocytic leukemia and quantum chemical and docking calculations

Abstract

The paper describes the synthesis of a new Schiff base As (III) complex followed by the encapsulation of Schiff base As (III) complex in liposomes. First, As (III) Schiff base complex was synthesized from gold crystal ligand in contact with Ascl3. Detailed characterization using Fourier transform infrared spectroscopy (FT-IR), Hydrogen-1 nuclear magnetic resonance (HNMR) and, Liquid chromatography–mass spectrometry (LC-MS) confirmed the successful synthesis of As (III) Schiff base complex. The physicochemical properties of liposomal formulations were characterized by Dynamic light scattering (DLS), Atomic force microscopy (AFM), and Transmission electron microscopy (TEM). Furthermore, Cytotoxicity results revealed higher cytotoxicity and lower IC50 for As (III) complex (2.004 μM) relative to ATO ones (3.968 μM). The expression of cell cycle genes and apoptosis were determined by Real-time technique. Moreover, the quantum chemical calculations of compounds were carried out to obtain information about the geometry and chemical reactivity by the DMol3 module in Materials studio 2017. Finally, docking calculations were performed with Formamidopyrimidine [fapy]-DNA glycosylase (Fpg) and Poly [ADP-ribose] polymerase-1 (PARP-1) to investigate the tendency of As (III) complex to bind to these two proteins. The results presented here may suggest further investigation for in vivo studies and successful targeted therapy.